35 results match your criteria: "Cancer Strategic Clinical Network[Affiliation]"

Harmonization of the Health and Risk Factor Questionnaire data of the Canadian Partnership for Tomorrow Project: a descriptive analysis.

CMAJ Open

April 2019

Research Institute of the McGill University Health Centre (Fortier, Dragieva, Saliba); Centre hospitalier de l'Université de Montréal (CHUM) Research Centre (Craig), Montréal, Que.; CancerControl Alberta and Cancer Strategic Clinical Network (Robson), Alberta Health Services; Department of Agricultural, Food and Nutritional Science (Robson), Faculty of Agricultural, Life and Environmental Sciences, University of Alberta, Edmonton, Alta.

Background: The Canadian Partnership for Tomorrow Project is a multistudy platform integrating the British Columbia Generations Project, Alberta's Tomorrow Project, the Ontario Health Study, CARTaGENE (Quebec) and the Atlantic Partnership for Tomorrow's Health. This paper describes the process used to harmonize the Health and Risk Factor Questionnaire data and provides an overview of the key information required to properly use the core data set generated.

Methods: This is a descriptive analysis of the harmonization process that was developed on the basis of the Maelstrom Research guidelines for retrospective harmonization.

View Article and Find Full Text PDF

Background: The purpose of this study was to optimize an existing clinical care pathway (CCP) for head and neck cancer with a high-observation protocol (HOP) and to determine the effect on length of intensive care unit (ICU) admission and length of stay in hospital (LOS).

Methods: The HOP mandated initiation of spontaneous breathing trials before the conclusion of the surgery, weaning of sedation, and limiting mechanical ventilation. All patients with head and neck cancer undergoing primary surgery on the HOP were compared to a historical cohort regarding length of ICU admission, ICU readmissions, and LOS.

View Article and Find Full Text PDF

Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations.

Plast Reconstr Surg

May 2017

Calgary, Alberta, and Toronto, Ontario, Canada; Duarte, Calif.; Recife, Pernambuco, Brazil; Ghent, Belgium; New York, N.Y.; and Örebro, Sweden.

Background: Enhanced recovery following surgery can be achieved through the introduction of evidence-based perioperative maneuvers. This review aims to present a consensus for optimal perioperative management of patients undergoing breast reconstructive surgery and to provide evidence-based recommendations for an enhanced perioperative protocol.

Methods: A systematic review of meta-analyses, randomized controlled trials, and large prospective cohorts was conducted for each protocol element.

View Article and Find Full Text PDF

Aims: To evaluate concordance, upgrades and downgrades from biopsy to prostatectomy, and associated clincopathological parameters, using the recently proposed Gleason grade groups/International Society of Urologic Pathology (ISUP) grades.

Methods And Results: We evaluated 2529 patients who underwent biopsy and prostatectomy in our institution from 2005 to 2014. A global grade group (GR)/Gleason score (GS) was used.

View Article and Find Full Text PDF

Importance: Head and neck cancers often require complex, labor-intensive surgeries, especially when free flap reconstruction is required. Enhanced recovery is important in this patient population but evidence-based protocols on perioperative care for this population are lacking.

Objective: To provide a consensus-based protocol for optimal perioperative care of patients undergoing head and neck cancer surgery with free flap reconstruction.

View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the rates and trends of early repeat resection (ERR) in patients with high-grade T1 bladder cancer (HGT1-BC) in Alberta from 2007 to 2011, revealing that only 27.8% of patients underwent ERR, though this rate increased over time.
  • Factors influencing the likelihood of receiving ERR included being younger than 80 and the specific medical center where the initial bladder tumor surgery occurred.
  • The study found that patients who received ERR had a significantly higher five-year overall survival rate (72.7%) compared to those who did not (55.3%), indicating a need for standardized clinical practices to improve outcomes across different regions.
View Article and Find Full Text PDF

Introduction: Survival in uveal melanoma has remained unchanged since the early 1970s. Because outcomes are highly related to the size of the tumour, timely and accurate diagnosis can increase the chance for cure.

Methods: A consensus-based guideline was developed to inform practitioners.

View Article and Find Full Text PDF

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

Curr Oncol

April 2015

Quebec: Hôpital Maisonneuve-Rosemont, Montreal (Kassis); Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal (Tagalakis); Department of Oncology, Faculty of Medicine, McGill University, Montreal (Kavan).

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy is used to treat vte; however, patients with cancer have unique clinical circumstances that can often make decisions surrounding the administration of therapeutic anticoagulation complicated. No national Canadian guidelines on the management of established cancer-associated thrombosis have been published.

View Article and Find Full Text PDF

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.

Curr Oncol

April 2015

Quebec: Hôpital Maisonneuve-Rosemont, Montreal (Kassis); Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal (Tagalakis); Department of Oncology, Faculty of Medicine, McGill University, Montreal (Kavan).

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy has been shown to prevent vte; however, unique clinical circumstances in patients with cancer can often complicate the decisions surrounding the administration of prophylactic anticoagulation. No national Canadian guidelines on the prevention of cancer-associated thrombosis have been published.

View Article and Find Full Text PDF